INCY - Incyte Non-GAAP EPS of $1.01 beats by $0.27 revenue of $911.4M beats by $93.15M
- Incyte press release ( NASDAQ: INCY ): Q2 Non-GAAP EPS of $1.01 beats by $0.27 .
- Revenue of $911.4M (+29.1% Y/Y) beats by $93.15M .
- Jakafi net product revenue guidance range of $2.36B to $2.4B for 2022 (prior $2.33B - $2.4B).
- “The second quarter was strong with total revenues up 29% year-over-year, multiple approvals and the continued advancement of our pipeline. The launch of Opzelura in atopic dermatitis continues to progress well and in recent weeks, improvements in reimbursement have translated into an increase in covered claims. Revenues in the second quarter were temporarily impacted by the shift from free drug to paid prescription. Patient demand and satisfaction remain strong,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “In July, Opzelura was also approved by the FDA in nonsegmental vitiligo, creating a new growth opportunity as the first therapy approved for repigmentation of vitiligo.”
For further details see:
Incyte Non-GAAP EPS of $1.01 beats by $0.27, revenue of $911.4M beats by $93.15M